Brief: Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies Of Azenosertib
13/11/2024 13:05
Nov 13 (Reuters) - Zentalis Pharmaceuticals Inc
ZNTL.O :
* ZENTALIS PHARMACEUTICALS ANNOUNCES EXECUTIVE LEADERSHIP
CHANGES
SUPPORTING PLANNED REGISTRATIONAL CLINICAL STUDIES OF
AZENOSERTIB
* ZENTALIS PHARMACEUTICALS INC - JULIE EASTLAND APPOINTED
CEO,
PRESIDENT AND DIRECTOR
* ZENTALIS PHARMACEUTICALS INC - SCOTT MYERS APPOINTED
CHAIRPERSON
OF BOARD
Source text: ID:nGNX1pq9LR
Further company coverage: ZNTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer